PT3546458T - Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina e ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inibidores de cdk4/6 para tratamento p.e. da artrite reumatoide, arteriosclerose, fibrose pulmonar, enfarte cerebral ou cancro - Google Patents

Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina e ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inibidores de cdk4/6 para tratamento p.e. da artrite reumatoide, arteriosclerose, fibrose pulmonar, enfarte cerebral ou cancro

Info

Publication number
PT3546458T
PT3546458T PT178741658T PT17874165T PT3546458T PT 3546458 T PT3546458 T PT 3546458T PT 178741658 T PT178741658 T PT 178741658T PT 17874165 T PT17874165 T PT 17874165T PT 3546458 T PT3546458 T PT 3546458T
Authority
PT
Portugal
Prior art keywords
pyrido
pharmaceutically acceptable
acceptable salt
pyrimidine derivative
pyrimidine
Prior art date
Application number
PT178741658T
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of PT3546458T publication Critical patent/PT3546458T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
PT178741658T 2016-11-28 2017-11-27 Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina e ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inibidores de cdk4/6 para tratamento p.e. da artrite reumatoide, arteriosclerose, fibrose pulmonar, enfarte cerebral ou cancro PT3546458T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016229969 2016-11-28

Publications (1)

Publication Number Publication Date
PT3546458T true PT3546458T (pt) 2021-02-25

Family

ID=62194988

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178741658T PT3546458T (pt) 2016-11-28 2017-11-27 Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina e ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inibidores de cdk4/6 para tratamento p.e. da artrite reumatoide, arteriosclerose, fibrose pulmonar, enfarte cerebral ou cancro

Country Status (28)

Country Link
US (1) US11084814B2 (pt)
EP (1) EP3546458B1 (pt)
JP (1) JP6785876B2 (pt)
KR (1) KR102290815B1 (pt)
CN (1) CN110036012B (pt)
AR (1) AR110238A1 (pt)
AU (1) AU2017364807B2 (pt)
BR (1) BR112019010674A2 (pt)
CA (1) CA3043561A1 (pt)
CL (1) CL2019001419A1 (pt)
CO (1) CO2019005514A2 (pt)
CY (1) CY1123850T1 (pt)
DK (1) DK3546458T3 (pt)
ES (1) ES2852123T3 (pt)
HR (1) HRP20210285T1 (pt)
HU (1) HUE053220T2 (pt)
IL (1) IL266312B (pt)
LT (1) LT3546458T (pt)
MX (1) MX2019005803A (pt)
MY (1) MY196497A (pt)
PH (1) PH12019501171A1 (pt)
PL (1) PL3546458T3 (pt)
PT (1) PT3546458T (pt)
SA (1) SA519401827B1 (pt)
SI (1) SI3546458T1 (pt)
TW (1) TWI799399B (pt)
WO (1) WO2018097297A1 (pt)
ZA (1) ZA201902893B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022037592A1 (zh) * 2020-08-17 2022-02-24 南京明德新药研发有限公司 嘧啶并环类化合物
CN113636973B (zh) * 2021-09-07 2023-04-07 山东铂源药业股份有限公司 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法
WO2023155841A1 (zh) * 2022-02-16 2023-08-24 南京明德新药研发有限公司 嘧啶并环类化合物的盐型、晶型
WO2024020419A1 (en) * 2022-07-18 2024-01-25 Iambic Therapeutics, Inc. Aza-quinazoline compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
ME01282B (me) 2008-08-22 2013-06-20 Novartis Ag Jedinjenja pirolopirimidina kao inhibitori cdk
JP2012504646A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
US9249123B2 (en) 2010-09-01 2016-02-02 Genentech, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN104470921B (zh) * 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
JP6559132B2 (ja) 2013-08-23 2019-08-14 ニューファーマ， インコーポレイテッド ある特定の化学的実体、組成物および方法
US9914839B2 (en) * 2013-09-30 2018-03-13 Certainteed Corporation Stain repellent and VOC eliminating coatings and use thereof
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US9828373B2 (en) * 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN107614499B (zh) * 2015-05-29 2020-09-18 帝人制药株式会社 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐

Also Published As

Publication number Publication date
AU2017364807A1 (en) 2019-05-16
CL2019001419A1 (es) 2019-08-30
CO2019005514A2 (es) 2019-07-31
SI3546458T1 (sl) 2021-03-31
ES2852123T3 (es) 2021-09-13
PH12019501171A1 (en) 2021-02-08
IL266312B (en) 2021-08-31
KR20190066631A (ko) 2019-06-13
US20190367510A1 (en) 2019-12-05
RU2019116137A3 (pt) 2021-08-13
EP3546458B1 (en) 2021-01-06
PL3546458T3 (pl) 2021-06-14
JPWO2018097297A1 (ja) 2019-06-24
EP3546458A4 (en) 2019-10-09
CN110036012A (zh) 2019-07-19
RU2019116137A (ru) 2020-11-27
CA3043561A1 (en) 2018-05-31
US11084814B2 (en) 2021-08-10
DK3546458T3 (da) 2021-02-22
TWI799399B (zh) 2023-04-21
WO2018097297A1 (ja) 2018-05-31
TW201831476A (zh) 2018-09-01
JP6785876B2 (ja) 2020-11-18
AR110238A1 (es) 2019-03-13
EP3546458A1 (en) 2019-10-02
ZA201902893B (en) 2020-01-29
SA519401827B1 (ar) 2022-07-28
AU2017364807B2 (en) 2021-05-13
CY1123850T1 (el) 2022-05-27
HRP20210285T1 (hr) 2021-04-02
BR112019010674A2 (pt) 2019-10-01
MY196497A (en) 2023-04-17
HUE053220T2 (hu) 2021-06-28
IL266312A (en) 2019-06-30
KR102290815B1 (ko) 2021-08-18
CN110036012B (zh) 2022-05-10
LT3546458T (lt) 2021-05-10
MX2019005803A (es) 2019-09-10

Similar Documents

Publication Publication Date Title
IL255488B (en) Pyrido[4,3-di]pyrimidine derivative and its pharmaceutically acceptable salt
ZA201905456B (en) Pyrrolo[1,2-b]pyridazine derivatives
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
ZA201902893B (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
EP3173412A4 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
ZA201900236B (en) Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
ZA201902828B (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose